COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > There's a recent SCHEDULE 13D filing of interest

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Sep 07, 2024 10:28pm

89 Views

Post# 36213507

RE:There's a recent SCHEDULE 13D filing of interest

The fund owning shares...

Peter Puccetti is a prominent figure in the Canadian investment management industry, primarily known for his role at Goodwood Inc. Here's what we know about him:

Professional Background

Peter Puccetti is the founder, Chairman, and Chief Investment Officer (CIO) of Goodwood Inc., an independent investment management firm based in Toronto. He established Goodwood in 1996 with a focus on value investment methodology.

Investment Approach

Puccetti is known for his value-oriented investment style:

He considers himself a value manager who can also sell stocks short.
His approach is described as bottom-up, company-specific, and often event-driven.
Puccetti focuses on a limited number of core positions, typically 8-10, which often represent over 50% of the portfolio.

Fund Management

Puccetti has been managing the flagship Goodwood Fund since its inception. This fund aims to maximize long-term total returns through the purchase and short sale of primarily North American exchange-listed securities.

Performance

The Goodwood Fund, under Puccetti's management, has shown impressive performance:

From its October 1996 inception through April 30 (year not specified), the fund achieved a 20.1% average annual return, compared to 4.2% for the S&P/TSX Composite Total-Return Index.

Investment Experience

Puccetti has over 30 years of investment experience, with a particular focus on special situations value investing.

Board Experience

He has served on a number of public and private boards, leveraging his investment expertise.

Educational Background

Puccetti holds the Chartered Financial Analyst (CFA) designation.

Company Ownership

As of 2012, Puccetti was increasing his indirect interest in Goodwood to a controlling 97.2% by purchasing shares from existing shareholders.Peter Puccetti's long-standing leadership at Goodwood Inc. and his track record in fund management have established him as a notable figure in the Canadian investment landscape.